

October 1, 2020

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 001 Scrip Code: 512529	National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai – 400 051 Symbol: SEQUENT
--	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Consolidation of Shareholding in Fendigo BV, Netherlands to make Fendigo BV a Wholly Owned Subsidiary of the Company

Please find attached disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, consequent to entering into definitive agreement with Mr. Servatius Justinus Cornelius Maria Van Der Heijden for the acquisition of 15% stake from him in Fendigo BV through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company.

On completion of the proposed acquisition, Fendigo BV will become a Wholly Owned Subsidiary of the Company.


The said transaction is expected to be completed on or before October 31, 2020.

We request you to take the above on your record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah

Company Secretary & Compliance Officer



SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Acquisition of Incremental Stake of 15% in Fendigo BV, a subsidiary of the Company

Sr. No	Particulars	
1.	Name of the Target entity, details in brief such as size, turnover etc.	<p>Name of the Target Company:</p> <p>FENDIGO BV</p> <p>Details of Target Company:</p> <p>Fendigo BV, located at Netherlands, is a trading and distribution arm for animal health products.</p> <p>FY 2019-20 Financials:</p> <p>Sales: ₹ 126.13 Mn EBIDTA: ₹ 11.27 Mn Net Profit: ₹ 9.47 Mn Net Cash: ₹ 30.80 Mn</p>
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition	<p>The object of acquisition is to consolidate the Shareholding in Fendigo BV.</p> <p>The Company currently holds 85% stake in Fendigo BV and consequent to this acquisition, Fendigo BV will become a Wholly Owned Subsidiary of the Company.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No
6.	Indicative time period for completion	On or before October 31, 2020
7.	Nature of consideration	Cash transaction

Krishab



8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	The Company will acquire 15% stake in Fendigo BV through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company	
9.	Cost of acquisition or the price at which the shares are acquired	EUR 191,947.50 (One Hundred Ninety One Thousand Nine Hundred Forty Seven euro and 50 eurocents)	
10.			
a.	Products/line of business acquired	Brief Background: Fendigo is a veterinary pharmaceutical Company operating in the Benelux region. The Company is involved in sales and marketing of veterinary and health products for pets, farm animals, horses and poultry. By a wide portfolio of products Fendigo responds to the actual needs of veterinarians, farmers and other parties of the Animal Health Sector. Line of Business: Pharmaceuticals	
b.	Date of incorporation	14-12-2000	
c.	History of last 3 years turnover (₹ in millions)	FY 2019-20	126.13
		FY 2018-19	115.55
		FY 2017-18	111.16
d.	Country in which the acquired entity has presence	Netherlands	

Krishab

